Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127894342 | 12789434 | 2 | F | 20070403 | 20160927 | 20160928 | 20160929 | EXP | PHHO2007AU023105 | NOVARTIS | 60.34 | YR | F | Y | 0.00000 | 20160929 | MD | AU | AU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127894342 | 12789434 | 1 | PS | TYKERB | LAPATINIB DITOSYLATE | 1 | Oral | 1500 MG, QD | 1332000 | MG | N | 0 | 1500 | MG | QD | ||||
| 127894342 | 12789434 | 2 | SS | LETROZOLE. | LETROZOLE | 1 | Oral | 2.5 MG, QD | 2220.48511 | MG | 0 | 2.5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127894342 | 12789434 | 1 | Breast cancer metastatic |
| 127894342 | 12789434 | 2 | Breast cancer metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127894342 | 12789434 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127894342 | 12789434 | Ejection fraction decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127894342 | 12789434 | 1 | 20041028 | 20070430 | 0 | |
| 127894342 | 12789434 | 2 | 20041028 | 20070430 | 0 |